RxDoctor Payments Data

Jessica Heestand, MD

Internal Medicine · Raleigh, NCNPI 1902167208

Payments from drug & device makers

$971in general payments, 2019–2025

Across 64 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$196
  • Lilly USA, LLC$175
  • Johnson & Johnson$147
  • Abbott$115
  • Grifols USA, LLC$33
  • GSK$33
  • plus $272 from 13 others

What the payments were for

  • Food & beverage$969100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$971 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$183,863
Medicare patients
306
Services billed
6,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$78,889
MounjaroTirzepatide65$77,277
EliquisApixaban64$64,765
JardianceEmpagliflozin45$55,105
TrulicityDulaglutide27$27,438
MyrbetriqMirabegron22$25,473
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$19,955
LinzessLinaclotide16$19,414
Breo ElliptaFluticasone/Vilanterol40$17,516
XareltoRivaroxaban12$16,808
Janumet XrSitagliptin Phos/Metformin Hcl16$12,339
SynthroidLevothyroxine Sodium111$10,418
PremarinEstrogens, Conjugated15$6,910
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,384
FarxigaDapagliflozin Propanediol11$6,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$175$104,71592 claims
Novo NordiskOzempic$196$78,88964 claims
PfizerEliquis, Premarin, Paxlovid$23$77,33097 claims
Boehringer IngelheimJardiance$29$55,10545 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$33$43,85573 claims
AbbVieLinzess, Synthroid$22$29,831127 claims
MerckJanumet Xr, Belsomra$15$17,41028 claims
Johnson & JohnsonXarelto$147$16,80812 claims
AstraZenecaFarxiga$28$6,00711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →